Icahn: Forest Labs CEO Sold $500 Million in Stock Before Lexapro Patent Loss
Icahn: Forest Labs CEO Sold 0 Million in Stock Before Lexapro Patent Loss Carl Icahn accused drug maker Forest Laboratories Inc. (FRX) Chief Executive Howard Solomon of selling more than $ 500 million...
View ArticleSFU grad hyped erectile dysfunction stock under assumed name
SFU grad hyped erectile dysfunction stock under assumed name In November 2009, I reported that Vancouver-based Global Health Ventures Inc., which claims to be developing a drug to treat erectile...
View ArticleForest Laboratories Stock Rating Reaffirmed by Zacks (FRX)
Forest Laboratories Stock Rating Reaffirmed by Zacks (FRX) Zacks' analyst wrote, “Forest is facing tough times with Lexapro losing patent protection. The company reported fourth quarter fiscal 2013...
View ArticleIs This Health Care Stock Underrated?
Is This Health Care Stock Underrated? Teva blamed lower sales of generic Lexapro, an antidepressant, and Avapro, a high blood pressure medication, for its top line decline in the United States. It...
View ArticleNew Stock Coverage: Splash the Cash on Malibu Boats
New Stock Coverage: Splash the Cash on Malibu Boats His previous upbeat tomes include "Essays on the Great Depression," published in the stock market's utterly calamitous year of 2000. Little wonder...
View Article
More Pages to Explore .....